Lexicon Pharmaceuticals, Inc.LXRXNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts are neutral — opinion is divided on direction.

Consensus Rating

Hold

14 analysts·Moderate coverage

36%

Rating Distribution

Strong Buy

00%

Buy

536%

Hold

750%

Sell

214%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 417% higher.

Bear Case

$6.00

+417%

Consensus

$6.00

+417%

Bull Case

$6.00

+417%

Price Range14 analysts

Low

Consensus

High

$6.00

Current Target

Current Price

$1.16

Upside to Target

$4.84

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-0.24(4 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+16.23%

EPS—

FY2028

Rev+149.90%

EPS—

FY2029

Rev+74.36%

EPS—

Earnings Surprises

Beat rate:58%(7/12 quarters)

Avg surprise:+13.8%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Oct 18, 2024Leerink Partners

Lexicon Pharmaceuticals (LXRX) PT Raised to $6 at Leerink Partners

Target:$6.00

+198.5%from $2.01

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance